Direvo CEO Thomas von Ruden: An Interview With “The Pink Sheet” DAILY
This article was originally published in The Pink Sheet Daily
Executive Summary
In first installment of interview, von Ruden discusses Direvo’s technology focus and how it came to center on Factor VIII and Factor IX.
You may also be interested in...
Direvo CEO Thomas von Ruden: An Interview With “The Pink Sheet” DAILY
In this second installment, von Ruden discusses why Bayer decided to purchase Direvo.
Direvo CEO Thomas von Ruden: An Interview With “The Pink Sheet” DAILY
In this second installment, von Ruden discusses why Bayer decided to purchase Direvo.
Bayer Beefs Up Biologics Pipeline With Direvo Biotech Buy
Separate spin-out transaction establishes Direvo’s industrial biotech business as an independent entity.